Alk fusion partners

Merrida A.

Diagnostic Pathology volume 17 , Article number: 27 Cite this article. Metrics details. However, co-occurrence of double ALK fusions in one patient was rare. In both patients, tumor cells displayed strong expression of ALK protein. Genetic profiling by next generation sequencing showed both patients concurrently harbored two types of ALK rearrangements.

Alk fusion partners

Federal government websites often end in. The site is secure. Preview improvements coming to the PMC website in October Learn More or Try it out now. Thirty-four of the distinct fusion partners are located on the short arm of chromosome 2; 28 of these 34 fusion partners are located on 2p, in which ALK is located on 2p In addition, at least 28 intergenic ALK rearrangements have also been reported, with three of them reported as responding to crizotinib. We aim to update and improve the list going forward. In this article, we have compiled a list of the ALK fusion partners including intergenic rearrangements identified in the literature for easy reference. Overall, a total of 90 distinct ALK fusion partners including noncoding RNAs have been identified in the literature by the end of January Table 1. Twenty-five intergenic rearrangements to exon 20 of ALK have also been identified and listed separately in Table 2.

The yellow arrow indicates a new meningeal metastasis lesion. Fibronectin, FN1 : glycoprotein found in a dimer or multimer at the cell surface and in extracellular alk fusion partners Himmelberg ; Stephen M.

Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Moreover, there are numerous reports of ALK inhibitor activity in multiple solid and hematologic tumors e. Many reports used crizotinib or alectinib, but each of the approved ALK inhibitors have shown activity.

Merrida A. Childress , Stephen M. Davies , Christine M. Mol Cancer Res 1 November ; 16 11 : — Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase ALK are detected in numerous tumor types. Biochemical and cellular assays were used to assess the efficacy of various ALK TKIs in clinical use, transformative phenotypes, and biochemical properties of each fusion.

Alk fusion partners

Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer. In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Anaplastic lymphoma kinase ALK is a potent oncogenic driver in lung cancer. Elucidation of on-target resistance mechanisms has facilitated the development of next-generation ALK inhibitors, but overcoming ALK-independent resistance mechanisms remains a challenge. This is a preview of subscription content, access via your institution. Howlader, N.

Thesaurus for sound

Salgia, S. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. ETV6 fusion genes in hematological malignancies: a review. Ramalingam S. Copy to clipboard. All patients carry ALK fusion events. Apart from the above-mentioned ALK inhibitor-dependent resistant mechanisms, there are ALK inhibitor independent resistance pathways. Prokoph, N. Yang, Received : 21 October Thorac Cancer Jun. The New England journal of medicine Jun. Case report Case 1 The patient was a year-old Chinese female without a history of smoking. Busam, K. Cao, Z.

Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase ALK are detected in numerous tumor types.

Copy to clipboard. MD PHD: 1. Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines. Oncologist 26 , e—e Childress, M. Download references. He, X. Few investigations have focused on the concomitance of double ALK rearrangements because of the low incidence. Togashi, 9. Article Navigation.